Saturday, October 1, 2022


Biotechnology News Magazine

Gandeeva Therapeutics announces search for new Chief Strategy Development Officer

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Pender & Howe, a North American executive search firm, is proud to lead the search for a Chief Strategy Development Officer on behalf of Gandeeva Therapeutics.

Directly supporting Gandeeva’s CEO, the Chief Strategy Development Officer (CSDO) will oversee the company’s strategic development objectives. Unlike a traditional Chief Scientific Officer, this unique opportunity will enable the CSDO to help define and execute the company’s scientific and corporate development strategy in collaboration with world-class scientists and industry leaders at Gandeeva.

Gandeeva Therapeutics is a rapidly growing biotechnology company that seeks to harness the power of cryo-EM technology and machine learning to design better drugs. The company’s platform overcomes limitations in using X-ray crystallography for drug design and avoids discovery dead ends that can arise from computational docking methods in the absence of experimental validation.

Gandeeva’s AI/ML-driven workflows enable high throughput structure determination combined with innovative biochemical methods to explore low-data targets, membrane proteins and protein complexes. From small molecules that induce protein proximity to engineered antibodies, Gandeeva’s approach breaks new ground to develop precision medicines for our most challenging diseases.

Gandeeva is headquartered in a 22,000 sq. ft. building in Greater Vancouver, British Columbia, set to be fully operational by December 2022.

Position details can be found here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine